Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 980250, 15 pages
http://dx.doi.org/10.1155/2012/980250
Review Article

scFv Antibody: Principles and Clinical Application

1Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia
2Institute of Bioscience, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia
3Faculty of Agriculture and Biotechnology, Universiti Sultan Zainal Abidin, Kampus Kota, Jalan Sultan Mahmud, 20400 Kuala Terengganu, Malaysia
4Department of Bioprocess Technology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor, 43400 Serdang, Malaysia

Received 10 November 2011; Accepted 7 January 2012

Academic Editor: T. Nakayama

Copyright © 2012 Zuhaida Asra Ahmad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Janeway, P. Travers, M. Walport et al., Immunobiology, Garland Publishing, 5th edition, 2001.
  2. I. B. Rogozin, V. V. Solovyov, and N. A. Kolchanov, “Somatic hypermutagenesis in immunoglobulin genes. I. Correlation between somatic mutations and repeats. Somatic mutation properties and clonal selection,” Biochimica et Biophysica Acta, vol. 1089, no. 2, pp. 175–182, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. D. S. Dimitrov and J. D. Marks, “Therapeutic antibodies: current state and future trends—is a paradigm change coming soon?” Methods in Molecular Biology, vol. 525, pp. 1–27, 2009. View at Google Scholar · View at Scopus
  4. M. A. Boss, J. H. Kenten, C. R. Wood, and J. S. Emtage, “Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in Escherichia coli,” Nucleic Acids Research, vol. 12, no. 9, pp. 3791–3806, 1984. View at Publisher · View at Google Scholar
  5. R. E. Kontermann and R. Müller, “Intracellular and cell surface displayed single-chain diabodies,” Journal of Immunological Methods, vol. 226, no. 1-2, pp. 179–188, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Gram, L. A. Marconi, C. F. Barbas, T. A. Collet, R. A. Lerner, and A. S. Kang, “in vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 8, pp. 3576–3580, 1992. View at Google Scholar · View at Scopus
  7. A. Klimka, B. Matthey, R. C. Roovers et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” British Journal of Cancer, vol. 83, no. 2, pp. 252–260, 2000. View at Google Scholar · View at Scopus
  8. N. A. Watkins and W. H. Ouwehand, “Introduction to antibody engineering and phage display,” Vox Sanguinis, vol. 78, no. 2, pp. 72–79, 2000. View at Google Scholar · View at Scopus
  9. V. Feys, P. de Waele, A. van de Voorde, P. Casneuf, and W. Fiers, “Expression of functional mouse antibodies directed against the tumour marker human placental alkaline phosphatase in non-lymphoid cells,” International Journal of Cancer, vol. 41, no. 2, pp. 26–27, 1988. View at Google Scholar · View at Scopus
  10. S. J. M. O'Connor, P. D. Forsyth, S. Dalal et al., “The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody,” British Journal of Haematology, vol. 99, no. 3, pp. 597–604, 1997. View at Google Scholar · View at Scopus
  11. S. Cabilly, A. D. Riggs, and H. Pande, “Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 11 I, pp. 3273–3277, 1984. View at Google Scholar · View at Scopus
  12. A. Skerra and A. Plückthun, “Assembly of a functional immunoglobulin Fv fragment in Escherichia coli,” Science, vol. 240, no. 4855, pp. 1038–1041, 1988. View at Google Scholar · View at Scopus
  13. M. Better, C. P. Chang, R. R. Robinson, and A. H. Horwitz, “Escherichia coli secretion of an active chimeric antibody fragment,” Science, vol. 240, no. 4855, pp. 1041–1043, 1988. View at Google Scholar · View at Scopus
  14. J. McCafferty, A. D. Griffiths, G. Winter, and D. J. Chiswell, “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature, vol. 348, no. 6301, pp. 552–554, 1990. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ho, S. Nagata, and I. Pastan, “Isolation of anti-CD22 Fv with high affinity by Fv display on human cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 25, pp. 9637–9642, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Galeffi, A. Lombardi, I. Pietraforte et al., “Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems,” Journal of Translational Medicine, vol. 4, article no. 39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. B. H. Choo, R. D. Dunn, K. W. Broady, and R. L. Raison, “Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells,” Protein Expression and Purification, vol. 24, no. 3, pp. 338–347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. J. S. Huston, A. J. T. George, G. P. Adams et al., “Single-chain Fv radioimmunotargeting,” Quarterly Journal of Nuclear Medicine, vol. 40, no. 3, pp. 320–333, 1996. View at Google Scholar · View at Scopus
  19. S. Dana Jones and W. A. Marasco, “Antibodies for targeted gene therapy: extracellular gene targeting and intracellular expression,” Advanced Drug Delivery Reviews, vol. 31, no. 1-2, pp. 153–170, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Colcher, G. Pavlinkova, G. Beresford, B. J. M. Booth, A. Choudhury, and S. K. Batra, “Pharmacokinetics and biodistribution of genetically-engineered antibodies,” Quarterly Journal of Nuclear Medicine, vol. 42, no. 4, pp. 225–241, 1998. View at Google Scholar · View at Scopus
  21. P. J. Hudson, “Recombinant antibody fragments,” Current Opinion in Biotechnology, vol. 9, no. 4, pp. 395–402, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. P. J. Hudson, “Recombinant antibody constructs in cancer therapy,” Current Opinion in Immunology, vol. 11, no. 5, pp. 548–557, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Little, S. M. Kipriyanov, F. Le Gall, and G. Moldenhauer, “Of mice and men: hybridoma and recombinant antibodies,” Immunology Today, vol. 21, no. 8, pp. 364–370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Hust, T. Jostock, C. Menzel et al., “Single chain Fab (scFab) fragment,” BMC Biotechnology, vol. 7, article no. 14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Glockshuber, M. Malia, I. Pfitzinger, and A. Plückthun, “A comparison of strategies to stabilize immunoglobulin Fv-fragments,” Biochemistry, vol. 29, no. 6, pp. 1362–1367, 1990. View at Google Scholar · View at Scopus
  26. K. Petrov, M. Dion, L. Hoffmann, T. Dintinger, A. Defontaine, and C. Tellier, “Bivalent Fv antibody fragments obtained by substituting the constant domains of a fab fragment with heterotetrameric molybdopterin synthase,” Journal of Molecular Biology, vol. 341, no. 4, pp. 1039–1048, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Furuta, M. Uchikawa, Y. Ueda et al., “Construction of mono- and bivalent human single-chain Fv fragments against the D antigen in the Rh blood group: multimerization effect on cell agglutination and application to blood typing,” Protein Engineering, vol. 11, no. 3, pp. 233–241, 1998. View at Google Scholar · View at Scopus
  28. P. J. Hudson and A. A. Kortt, “High avidity scFv multimers; diabodies and triabodies,” Journal of Immunological Methods, vol. 231, no. 1-2, pp. 177–189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Pluckthun and P. Pack, “New protein engineering approaches to multivalent and bispecific antibody fragments,” Immunotechnology, vol. 3, no. 2, pp. 83–105, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. A. D. Griffiths and A. R. Duncan, “Strategies for selection of antibodies by phage display,” Current Opinion in Biotechnology, vol. 9, no. 1, pp. 102–108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Huston, M. Mudgett-Hunter, M. S. Tai et al., “Protein engineering of single-chain Fv analogs and fusion proteins,” Methods in Enzymology, vol. 203, pp. 46–88, 1991. View at Google Scholar · View at Scopus
  32. R. E. Bird, K. D. Hardman, J. W. Jacobson et al., “Single-chain antigen-binding proteins,” Science, vol. 241, no. 4877, pp. 423–426, 1988. View at Google Scholar · View at Scopus
  33. K. Takkinen, M. L. Laukkanen, D. Sizmann et al., “An active single-chain antibody containing a cellulase linker domain is secreted by Escherichia coli,” Protein Engineering, vol. 4, no. 7, pp. 837–841, 1991. View at Google Scholar · View at Scopus
  34. J. E. Smallshaw, F. Georges, J. S. Lee, and E. B. Waygood, “Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42. Determination of binding constants with wild-type and mutant HPrs,” Protein Engineering, vol. 12, no. 7, pp. 623–630, 1999. View at Google Scholar · View at Scopus
  35. P. Argos, “An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion,” Journal of Molecular Biology, vol. 211, no. 4, pp. 943–958, 1990. View at Google Scholar · View at Scopus
  36. M. Whitlow, B. A. Bell, S. L. Feng et al., “An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability,” Protein Engineering, vol. 6, no. 8, pp. 989–995, 1993. View at Google Scholar · View at Scopus
  37. J. S. Huston, D. Levinson, M. Mudgett-Hunter et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 16, pp. 5879–5883, 1988. View at Google Scholar · View at Scopus
  38. V. K. Chaudhary, J. K. Batra, M. G. Gallo, M. C. Willingham, D. J. FitzGerald, and I. Pastan, “A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 3, pp. 1066–1070, 1990. View at Google Scholar · View at Scopus
  39. X. K. Deng, L. A. Nesbit, and K. J. Morrow Jr., “Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system,” Clinical and Diagnostic Laboratory Immunology, vol. 10, no. 4, pp. 587–595, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Clackson, H. R. Hoogenboom, A. D. Griffiths, and G. Winter, “Making antibody fragments using phage display libraries,” Nature, vol. 352, no. 6336, pp. 624–628, 1991. View at Publisher · View at Google Scholar · View at Scopus
  41. V. K. Chaudhary, C. Queen, R. P. Junghans, T. A. Waldmann, D. J. FitzGerald, and I. Pastan, “A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin,” Nature, vol. 339, no. 6223, pp. 394–397, 1989. View at Google Scholar · View at Scopus
  42. W. J. J. Finlay, L. Shaw, J. P. Reilly, and M. Kane, “Generation of high-affinity chicken single-chain Fv antibody fragments for measurement of the Pseudonitzschia pungens toxin domoic acid,” Applied and Environmental Microbiology, vol. 72, no. 5, pp. 3343–3349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. J. D. Marks, H. R. Hoogenboom, T. P. Bonnert, J. McCafferty, A. D. Griffiths, and G. Winter, “By-passing immunization: human antibodies from V-gene libraries displayed on phage,” Journal of Molecular Biology, vol. 222, no. 3, pp. 581–597, 1991. View at Google Scholar · View at Scopus
  44. M. Shadidi and M. Sioud, “An anti-leukemic single chain fv antibody selected from a synthetic human phage antibody library,” Biochemical and Biophysical Research Communications, vol. 280, no. 2, pp. 548–552, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. J. L. Zhang, J. J. Guo, Z. Y. Zhang et al., “Screening and evaluation of human single-chain fragment variable antibody against hepatitis B virus surface antigen,” Hepatobiliary and Pancreatic Diseases International, vol. 5, no. 2, pp. 237–241, 2006. View at Google Scholar · View at Scopus
  46. K. Dai, H. Zhu, and C. Ruan, “Generation and characterization of recombinant single chain Fv antibody that recognizes platelet glycoprotein Ibα,” Thrombosis Research, vol. 109, no. 2-3, pp. 137–144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Hu, R. O'Dwyer, and J. G. Wall, “Cloning, expression and characterisation of a single-chain Fv antibody fragment against domoic acid in Escherichia coli,” Journal of Biotechnology, vol. 120, no. 1, pp. 38–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sheikholvaezin, P. Sandström, D. Eriksson, N. Norgren, K. Riklund, and T. Stigbrand, “Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase,” Hybridoma, vol. 25, no. 4, pp. 181–192, 2006. View at Google Scholar · View at Scopus
  49. D. Luo, N. Mah, M. Krantz et al., “VI-linker-Vh orientation-dependent expression of single chain Fv containing an engineered disulfide-stabilized bond in the framework regions,” Journal of Biochemistry, vol. 118, no. 4, pp. 825–831, 1995. View at Google Scholar · View at Scopus
  50. D. F. Lake, K. S. Lam, L. Peng, and E. M. Hersh, “Molecular cloning, expression and mutagenesis of an anti-insulin single chain Fv (scFv),” Molecular Immunology, vol. 31, no. 11, pp. 845–856, 1994. View at Publisher · View at Google Scholar · View at Scopus
  51. R. M. Horton, H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease, “Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension,” Gene, vol. 77, no. 1, pp. 61–68, 1989. View at Google Scholar · View at Scopus
  52. R. D. LeBoeuf, F. S. Galin, S. K. Hollinger, S. C. Peiper, and J. E. Blalock, “Cloning and sequencing of immunoglobulin variable-region genes using degenerate oligodeoxyribonucleotides and polymerase chain reaction,” Gene, vol. 82, no. 2, pp. 371–377, 1989. View at Google Scholar · View at Scopus
  53. G. G. Lilley, O. Dolezal, C. J. Hillyard, C. Bernard, and P. J. Hudson, “Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV,” Journal of Immunological Methods, vol. 171, no. 2, pp. 211–226, 1994. View at Publisher · View at Google Scholar · View at Scopus
  54. H. H. Hogrefe, R. L. Mullinax, A. E. Lovejoy, B. N. Hay, and J. A. Sorge, “A bacteriophage lambda vector for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage,” Gene, vol. 128, no. 1, pp. 119–126, 1993. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Kobayashi, M. Ohtoyo, E. Wada, Y. Kato, N. Mano, and J. Goto, “Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins,” Steroids, vol. 70, no. 4, pp. 285–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. C. D. Martin, G. Rojas, J. N. Mitchell et al., “A simple vector system to improve performance and utilisation of recombinant antibodies,” BMC Biotechnology, vol. 6, article no. 46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. P. L. Wang, B. K. C. Lo, and G. Winter, “Generating molecular diversity by homologous recombination in Escherichia coli,” Protein Engineering, Design and Selection, vol. 18, no. 8, pp. 397–404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Q. Guo, S. Y. You, L. Li, Y. Z. Zhang, J. N. Huang, and C. Y. Zhang, “Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli,” Journal of Biotechnology, vol. 102, no. 2, pp. 177–189, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Ravn, A. Danielczyk, K. Bak Jensen et al., “Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen,” Journal of Molecular Biology, vol. 343, no. 4, pp. 985–996, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Sakai, Y. Shimizu, T. Chiba et al., “Isolation and characterization of phage-displayed single chain antibodies recognizing nonreducing terminal mannose residues. 1. A new strategy for generation of anti-carbohydrate antibodies,” Biochemistry, vol. 46, no. 1, pp. 253–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. He, G. Zhou, K. D. Liu, and X. Y. Qin, “Construction and preliminary screening of a human phage single-chain antibody library associated with gastric cancer,” Journal of Surgical Research, vol. 102, no. 2, pp. 150–155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Verma, E. Boleti, and A. J. T. George, “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems,” Journal of Immunological Methods, vol. 216, no. 1-2, pp. 165–181, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. F. Baneyx, “Recombinant protein expression in Escherichia coli,” Current Opinion in Biotechnology, vol. 10, no. 5, pp. 411–421, 1999. View at Publisher · View at Google Scholar · View at Scopus
  64. C. W. Goulding and L. J. Perry, “Protein production in Escherichia coli for structural studies by X-ray crystallography,” Journal of Structural Biology, vol. 142, no. 1, pp. 133–143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. J. R. Swartz, “Advances in Escherichia coli production of therapeutic proteins,” Current Opinion in Biotechnology, vol. 12, no. 2, pp. 195–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. F. J.M. Mergulhão, G. A. Monteiro, J. M.S. Cabral, and M. A. Taipa, “Design of bacterial vector systems for the production of recombinant proteins in Escherichia coli,” Journal of Microbiology and Biotechnology, vol. 14, no. 1, pp. 1–14, 2004. View at Google Scholar
  67. R. K. C. Knaust and P. Nordlund, “Screening for soluble expression of recombinant proteins in a 96-well format,” Analytical Biochemistry, vol. 297, no. 1, pp. 79–85, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. S. A. Lesley, “High-throughput proteomics: protein expression and purification in the postgenomic world,” Protein Expression and Purification, vol. 22, no. 2, pp. 159–164, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Pluckthun, “Antibody engineering,” Current Opinion in Biotechnology, vol. 2, no. 2, pp. 238–246, 1991. View at Google Scholar
  70. J. Buchner and R. Rudolph, “Routes to active proteins from transformed microorganisms,” Current Opinion in Biotechnology, vol. 2, no. 4, pp. 532–538, 1991. View at Google Scholar · View at Scopus
  71. J. S. Huston, A. J. T. George, M. S. Tai et al., “Single-chain Fv design and production by preparative folding,” in Antibody Engineering, C. A. Borrebaeck, Ed., pp. 185–227, Oxford University Press, New York, NY, USA, 1995. View at Google Scholar
  72. H. Bothmann and A. Plückthun, “The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA: I. Increased functional expression of antibody fragments with and without cis-prolines,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 17100–17105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Bothmann and A. Plückthun, “Selection for a periplasmic factor improving phage display and functional periplasmic expression,” Nature Biotechnology, vol. 16, no. 4, pp. 376–380, 1998. View at Publisher · View at Google Scholar
  74. K. Ramm and A. Plückthun, “The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA: II. Isomerase-independent chaperone activity in vitro,” Journal of Biological Chemistry, vol. 275, no. 22, pp. 17106–17113, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. S. M. Aavula, S. V. Nimmagadda, N. Biradhar et al., “Generation and characterization of an scFv directed against site II of Rabies Glycoprotein,” Biotechnology Research International, vol. 2011, Article ID 652147, 11 pages, 2011. View at Publisher · View at Google Scholar
  76. L. Nieba, A. Honegger, C. Krebber, and A. Plückthun, “Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment,” Protein Engineering, vol. 10, no. 4, pp. 435–444, 1997. View at Google Scholar · View at Scopus
  77. A. Wörn and A. Plückthun, “An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly,” FEBS Letters, vol. 427, no. 3, pp. 357–361, 1998. View at Publisher · View at Google Scholar · View at Scopus
  78. G. P. Smith, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface,” Science, vol. 228, no. 4705, pp. 1315–1317, 1985. View at Google Scholar · View at Scopus
  79. C. C. Wu, E. H. Lin, Y. C. Lee et al., “Identification of a new peptide for fibrosarcoma tumor targeting and imaging in vivo,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 167045, 10 pages, 2010. View at Publisher · View at Google Scholar
  80. W. H. Wieland, D. Orzáez, A. Lammers, H. K. Parmentier, and A. Schots, “Display and selection of chicken IgA Fab fragments,” Veterinary Immunology and Immunopathology, vol. 110, no. 1-2, pp. 129–140, 2006. View at Publisher · View at Google Scholar
  81. S. I. Takemura, R. Asano, K. Tsumoto et al., “Construction of a diabody (small recombinant bispecific antibody) using a refolding system,” Protein Engineering, vol. 13, no. 8, pp. 583–588, 2000. View at Google Scholar · View at Scopus
  82. L. Xu, B. Q. Jin, and D. M. Fan, “Selection and identification of mimic epitopes for gastric cancer-associated antigen MG7 Ag,” Molecular Cancer Therapeutics, vol. 2, no. 3, pp. 301–306, 2003. View at Google Scholar · View at Scopus
  83. F. Rahbarizadeh, M. J. Rasaee, M. Forouzandeh Moghadam, A. A. Allameh, and E. Sadroddiny, “Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin,” Hybridoma and Hybridomics, vol. 23, no. 3, pp. 151–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Charlton, W. J. Harris, and A. J. Porter, “The isolation of super-sensitive anti-hapten antibodies from combinatorial antibody libraries derived from sheep,” Biosensors and Bioelectronics, vol. 16, no. 9-12, pp. 639–646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Okada, M. Akada, T. Fujita et al., “A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers,” Clinical Cancer Research, vol. 12, no. 1, pp. 191–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. T. J. Vaughan, A. J. Williams, K. Pritchard et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nature Biotechnology, vol. 14, no. 3, pp. 309–314, 1996. View at Google Scholar · View at Scopus
  87. M. D. Sheets, P. Amersdorfer, R. Finnern et al., “Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6157–6162, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Winter, A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom, “Making antibodies by phage display technology,” Annual Review of Immunology, vol. 12, pp. 433–455, 1994. View at Google Scholar · View at Scopus
  89. A. D. Griffiths, S. C. Williams, O. Hartley et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,” EMBO Journal, vol. 13, no. 14, pp. 3245–3260, 1994. View at Google Scholar · View at Scopus
  90. A. Knappik, L. Ge, A. Honegger et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” Journal of Molecular Biology, vol. 296, no. 1, pp. 57–86, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Völkel, R. Müller, and R. E. Kontermann, “Isolation of endothelial cell-specific human antibodies from a novel fully synthetic scFv library,” Biochemical and Biophysical Research Communications, vol. 317, no. 2, pp. 515–521, 2004. View at Publisher · View at Google Scholar
  92. J. Hanes and A. Plückthun, “In vitro selection and evolution of functional proteins by using ribosome display,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 4937–4942, 1997. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Hanes, C. Schaffitzel, A. Knappik, and A. Plückthun, “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nature Biotechnology, vol. 18, no. 12, pp. 1287–1292, 2000. View at Publisher · View at Google Scholar · View at Scopus
  94. A. S. Kang, C. F. Barbas, K. D. Janda, S. J. Benkovic, and R. A. Lerner, “Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 10, pp. 4363–4366, 1991. View at Google Scholar · View at Scopus
  95. H. R. Hoogenboom and P. Chames, “Natural and designer binding sites made by phage display technology,” Immunology Today, vol. 21, no. 8, pp. 371–378, 2000. View at Publisher · View at Google Scholar · View at Scopus
  96. H. R. Hoogenboom, A. P. De Brune, S. E. Hufton, R. M. Hoet, J. W. Arends, and R. C. Roovers, “Antibody phage display technology and its applications,” Immunotechnology, vol. 4, no. 1, pp. 1–20, 1998. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Yuan, P. Schulz, R. Liu, and M. R. Sierks, “Improved affinity selection using phage display technology and off-rate based selection,” Electronic Journal of Biotechnology, vol. 9, no. 2, pp. 171–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. J. R. McWhirter, A. Kretz-Rommel, A. Saven et al., “Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 4, pp. 1041–1046, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. R. E. Hawkins, S. R. Russel, and G. Winter, “Selection of phage antibodies of a structural epitope by using a peptide library displayed on filamentous bacteriophage,” Journal of Immunology, vol. 153, pp. 724–729, 1992. View at Google Scholar
  100. R. Schier, J. Bye, G. Apell et al., “Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection,” Journal of Molecular Biology, vol. 255, no. 1, pp. 28–43, 1996. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Jurado, V. De Lorenzo, and L. A. Fernández, “Thioredoxin fusions increase folding of single chain Fv antibodies in the cytoplasm of Escherichia coli: evidence that chaperone activity is the prime effect of thioredoxin,” Journal of Molecular Biology, vol. 357, no. 1, pp. 49–61, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Dueñas, L. -T. Chin, A. -C. Malmborg, R. Casalvilla, M. Ohlin, and C. A.K. Borrebaeck, “in vitro immunization of naive human B cells yields high affinity immunuglobulin G antibodies as illustrated by phage display,” Immunology, vol. 89, no. 1, pp. 1–7, 1996. View at Google Scholar
  103. A. Hemminki, S. Niemi, A. M. Hoffrén, L. Hakalahti, H. Söderlund, and K. Takkinen, “Specificity improvement of a recombinant anti-testosterone Fab fragment by CDRIII mutagenesis and phage display selection,” Protein Engineering, vol. 11, no. 4, pp. 311–319, 1998. View at Google Scholar · View at Scopus
  104. C. Krebber, S. Spada, D. Desplancq, and A. Pluckthun, “Co-selection of cognate antibody-antigen pairs by selectively-infective phages,” FEBS Letters, vol. 377, no. 2, pp. 227–231, 1995. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Hennecke, C. Krebber, and A. Plückthun, “Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology,” Protein Engineering, vol. 11, no. 5, pp. 405–410, 1998. View at Google Scholar · View at Scopus
  106. P. Lindner, K. Bauer, A. Krebber et al., “Specific detection of His-tagged proteins with recombinant anti-His tag scfv-phosphatase or scFv-phage fusions,” BioTechniques, vol. 22, no. 1, pp. 140–149, 1997. View at Google Scholar · View at Scopus
  107. A. Klimka, S. Barth, B. Matthey et al., “An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFV)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line,” British Journal of Cancer, vol. 80, no. 8, pp. 1214–1222, 1999. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Lekkerkerker and T. Logtenberg, “Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells,” Journal of Immunological Methods, vol. 231, no. 1-2, pp. 53–63, 1999. View at Publisher · View at Google Scholar · View at Scopus
  109. R. J. Giordano, M. Cardó-Vila, J. Lahdenranta, R. Pasqualini, and W. Arap, “Biopanning and rapid analysis of selective interactive ligands,” Nature Medicine, vol. 7, no. 11, pp. 1249–1253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. R. Beers, P. Chowdhury, D. Bigner, and I. Pastan, “Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display,” Clinical Cancer Research, vol. 6, no. 7, pp. 2835–2843, 2000. View at Google Scholar · View at Scopus
  111. S. G. Park, J. S. Lee, E. Y. Je, I. J. Kim, J. H. Chung, and I. H. Choi, “Affinity maturation of natural antibody using a chain shuffling technique and the expression of recombinant antibodies in Escherichia coli,” Biochemical and Biophysical Research Communications, vol. 275, no. 2, pp. 553–557, 2000. View at Publisher · View at Google Scholar
  112. A. D. Griffiths, M. Malmqvist, J. D. Marks et al., “Human anti-self antibodies with high specificity from phage display libraries,” EMBO Journal, vol. 12, no. 2, pp. 725–734, 1993. View at Google Scholar · View at Scopus
  113. P. Forrer, S. Jung, and A. Plückthun, “Beyond binding: using phage display to select for structure, folding and enzymatic activity in proteins,” Current Opinion in Structural Biology, vol. 9, no. 4, pp. 514–520, 1999. View at Publisher · View at Google Scholar
  114. J. B. Burritt, C. W. Bond, K. W. Doss, and A. J. Jesaitis, “Filamentous phage display of oligopeptide libraries,” Analytical Biochemistry, vol. 238, no. 1, pp. 1–13, 1996. View at Publisher · View at Google Scholar · View at Scopus
  115. L. F. Wang, M. Yu, and B. T. Eaton, “Epitope mapping and engineering using phage display technology,” Asia-Pacific Journal of Molecular Biology and Biotechnology, vol. 3, pp. 240–258, 1995. View at Google Scholar
  116. J. Sharon, “Structural correlates of high antibody affinity: three engineered amino acid substitutions can increase the affinity of an anti-p-azophenylarsonate antibody 200-fold,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 12, pp. 4814–4817, 1990. View at Publisher · View at Google Scholar · View at Scopus
  117. A. E. Willis, R. N. Perham, and D. Wraith, “Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage,” Gene, vol. 128, no. 1, pp. 79–83, 1993. View at Publisher · View at Google Scholar · View at Scopus
  118. K. Chester, B. Pedley, B. Tolner et al., “Engineering antibodies for clinical applications in cancer,” Tumor Biology, vol. 25, no. 1-2, pp. 91–98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  119. D. M. Goldenberg, “Targeted therapy of cancer with radiolabeled antibodies,” Journal of Nuclear Medicine, vol. 43, no. 5, pp. 693–713, 2002. View at Google Scholar · View at Scopus
  120. P. J. Hudson and C. Souriau, “Engineered antibodies,” Nature Medicine, vol. 9, no. 1, pp. 129–134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Yokota, D. E. Milenic, M. Whitlow, and J. Schlom, “Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms,” Cancer Research, vol. 52, no. 12, pp. 3402–3408, 1992. View at Google Scholar · View at Scopus
  122. N. Oriuchi, T. Higuchi, H. Hanaoka, Y. Iida, and K. Endo, “Current status of cancer therapy with radiolabeled monoclonal antibody,” Annals of Nuclear Medicine, vol. 19, no. 5, pp. 355–365, 2005. View at Google Scholar · View at Scopus
  123. E. Stipsanelli and P. Valsamaki, “Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach,” Hellenic Journal of Nuclear Medicine, vol. 8, no. 2, pp. 103–108, 2005. View at Google Scholar · View at Scopus
  124. M. K. Kim, H. J. Jeong, C. H. K. Kao et al., “Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications,” Nuclear Medicine and Biology, vol. 29, no. 2, pp. 139–146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. M. D. Winthrop, S. J. DeNardo, H. Albrecht et al., “Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy,” Clinical Cancer Research, vol. 9, no. 10, pp. 3845S–3853S, 2003. View at Google Scholar · View at Scopus
  126. P. S. Chowdhury, J. L. Viner, R. Beers, and I. Pastan, “Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 669–674, 1998. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Y. Liu, J. F. Eary, S. H. Petersdorf et al., “Follow-up of relapsed B-cell lymphoma patients treated with iodine-131- labeled anti-CD20 antibody and autologous stem-cell rescue,” Journal of Clinical Oncology, vol. 16, no. 10, pp. 3270–3278, 1998. View at Google Scholar · View at Scopus
  128. R. V. J. Chari, “Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy,” Advanced Drug Delivery Reviews, vol. 31, no. 1-2, pp. 89–104, 1998. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Gattenlöhner, H. Jörissen, M. Huhn et al., “A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 187621, 11 pages, 2010. View at Publisher · View at Google Scholar
  130. Q. Tong, K. Liu, X. M. Lu et al., “Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 121094, 8 pages, 2010. View at Publisher · View at Google Scholar
  131. N. J. V. Hansen, L. S. Pedersen, A. Stryhn, and S. Buus, “In situ cytokine therapy: redistribution of clonally expanded T cells,” European Journal of Immunology, vol. 31, no. 1, pp. 250–258, 2001. View at Publisher · View at Google Scholar
  132. W. Kaushik and R. J. Moots, “CDP-870 (certolizumab) in rheumatoid arthritis,” Expert Opinion on Biological Therapy, vol. 5, no. 4, pp. 601–606, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. W. J. Sandborn, B. G. Feagan, S. Stoinov et al., “Certolizumab pegol for the treatment of Crohn's disease,” New England Journal of Medicine, vol. 357, no. 3, pp. 228–238, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. M. Kuroki, F. Arakawa, P. D. Khare et al., “Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA,” Anticancer Research, vol. 20, no. 6 A, pp. 4067–4071, 2000. View at Google Scholar · View at Scopus
  135. X. Li, P. Stuckert, I. Bosch, J. D. Marks, and W. A. Marasco, “Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells,” Cancer Gene Therapy, vol. 8, no. 8, pp. 555–565, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. R. D. Alvarez, M. N. Barnes, J. Gomez-Navarro et al., “A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial,” Clinical Cancer Research, vol. 6, no. 8, pp. 3081–3087, 2000. View at Google Scholar · View at Scopus
  137. R. W. Strube and S. Y. Chen, “Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-Fc intrabodies,” Journal of Immunological Methods, vol. 263, no. 1-2, pp. 149–167, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. T. Gura, “Therapeutic antibodies: magic bullets hit the target,” Nature, vol. 417, pp. 584–586, 2002. View at Google Scholar
  139. Y. Izumi, L. Xu, E. di Tomaso et al., “Tumour biology: herceptin acts as an anti-angiogenic cocktail,” Nature, vol. 416, pp. 279–280, 2002. View at Google Scholar
  140. P. M. Cardarelli, Q. Maire, B. Dana et al., “Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines,” Cancer Immunology, Immunotherapy, vol. 51, no. 1, pp. 15–24, 2002. View at Publisher · View at Google Scholar
  141. C. L. Vogel, M. A. Cobleigh, and D. Tripathy, “Efficacy and safety of Herceptin (trastuzumab) as a single agent in first-line treatment of HER2-overexpressing in Metastatic Breast Cancer (HER2+/MBC),” Breast Cancer Research and Treatment, vol. 50, p. 232, 1998. View at Google Scholar
  142. S. Koido, Y. Tanaka, H. Tajiri, and J. Gong, “Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells,” Vaccine, vol. 25, no. 14, pp. 2610–2619, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. P. S. Chowdhury and H. Wu, “Tailor-made antibody therapeutics,” Methods, vol. 36, no. 1, pp. 11–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. R. E. Kontermann, M. G. Wing, and G. Winter, “Complement recruitment using bispecific diabodies,” Nature Biotechnology, vol. 15, no. 7, pp. 629–631, 1997. View at Google Scholar · View at Scopus
  145. P. A. Emanuel, J. Dang, J. S. Gebhardt et al., “Recombinant antibodies: a new reagent for biological agent detection,” Biosensors and Bioelectronics, vol. 14, no. 10-11, pp. 751–759, 2000. View at Publisher · View at Google Scholar · View at Scopus
  146. J. Luka, P. M. Arlen, and A. Bristol, “Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 934757, 8 pages, 2011. View at Publisher · View at Google Scholar
  147. H. R. Hoogenboom, A. D. Griffiths, K. S. Johnson, D. J. Chiswell, P. Hudson, and G. Winter, “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains,” Nucleic Acids Research, vol. 19, no. 15, pp. 4133–4137, 1991. View at Google Scholar · View at Scopus
  148. R. A. Griep, C. van Twisk, R. J. Kerschbaumer et al., “pSKAP/S: an expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins,” Protein Expression and Purification, vol. 16, no. 1, pp. 63–69, 1999. View at Publisher · View at Google Scholar · View at Scopus
  149. R. A. Griep, M. Prins, C. van Twisk et al., “Application of phage display in selecting Tomato spotted wilt virus-specific single-chain antibodies (scFvs) for sensitive diagnosis in ELISA,” Phytopathology, vol. 90, no. 2, pp. 183–190, 2000. View at Google Scholar · View at Scopus
  150. J. Liu, D. Wei, F. Qian et al., “pPIC9-Fc: a vector system for the production of single-chain Fv-Fc fusions in Pichia pastoris as detection reagents in vitro,” Journal of Biochemistry, vol. 134, no. 6, pp. 911–917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  151. R. J. Kerschbaumer, S. Hirschl, A. Kaufmann, M. Ibl, R. Koenig, and G. Himmler, “Single-chain Fv fusion proteins suitable as coating and detecting reagents in a double antibody sandwich enzyme-linked Immunosorbent assay,” Analytical Biochemistry, vol. 249, no. 2, pp. 219–227, 1997. View at Publisher · View at Google Scholar · View at Scopus
  152. K. Harper, R. L. Toth, M. A. Mayo, and L. Torrance, “Properties of a panel of single chain variable fragments against Potato leafroll virus obtained from two phage display libraries,” Journal of Virological Methods, vol. 81, no. 1-2, pp. 159–168, 1999. View at Publisher · View at Google Scholar · View at Scopus
  153. R. A. Griep, C. Van Twisk, J. M. Van Der Wolf, and A. Schots, “Fluobodies: green fluorescent single-chain Fv fusion proteins,” Journal of Immunological Methods, vol. 230, no. 1-2, pp. 121–130, 1999. View at Publisher · View at Google Scholar · View at Scopus
  154. K. Morino, H. Katsumi, Y. Akahori et al., “Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression,” Journal of Immunological Methods, vol. 257, no. 1-2, pp. 175–184, 2001. View at Google Scholar · View at Scopus
  155. P. Oelschlaeger, S. Srikant-Iyer, S. Lange, J. Schmitt, and R. D. Schmid, “Fluorophor-linked immunosorbent assay: a time- and cost-saving method for the characterization of antibody fragments using a fusion protein of a single-chain antibody fragment and enhanced green fluorescent protein,” Analytical Biochemistry, vol. 309, no. 1, pp. 27–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  156. R. E. Gross, “Breast cancer: risk factors, screening, and prevention,” Seminars in oncology nursing, vol. 16, no. 3, pp. 176–184, 2000. View at Google Scholar
  157. R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister, “American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1939–1955, 1999. View at Google Scholar · View at Scopus
  158. P. Carter, “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer, vol. 1, no. 2, pp. 118–129, 2001. View at Google Scholar · View at Scopus
  159. A. Ghadersohi, K. Chitta, W. R. Greco et al., “Tumor antigens and markers for breast and ovarian cancers,” Front Biosci, vol. 7, pp. 48–57, 2002. View at Google Scholar · View at Scopus
  160. L. G. Presta, “Engineering antibodies for therapy,” Current Pharmaceutical Biotechnology, vol. 3, no. 3, pp. 237–256, 2002. View at Publisher · View at Google Scholar
  161. S. P. Treon, N. Raje, and K. C. Anderson, “Immunotherapeutic strategies for the treatment of plasma cell malignancies,” Seminars in Oncology, vol. 27, no. 5, pp. 598–613, 2000. View at Google Scholar
  162. P. J. Yazaki, L. Shively, C. Clark et al., “Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications,” Journal of Immunological Methods, vol. 253, no. 1-2, pp. 195–208, 2001. View at Publisher · View at Google Scholar · View at Scopus
  163. A. M. Ali, B. K. Ong, K. Yusoff et al., “Generation of stable hybridoma clone secreting monoclonal antibody against breast cancer,” Journal of Molecular Microbiology and Biotechnology, vol. 4, no. 2, pp. 123–131, 1996. View at Google Scholar
  164. A. F. A. Bakar, N. B. Alitheen, Y. S. Keong, M. Hamid, S. A. M. Ali, and A. M. Ali, “A mouse igM monoclonal antibody recognizes breast and colon cancer,” Hybridoma, vol. 28, no. 3, pp. 199–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  165. N. Kida, T. Yoshimura, K. Mori, and K. Hayashi, “Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7),” Cancer Research, vol. 49, no. 13, pp. 3494–3498, 1989. View at Google Scholar · View at Scopus
  166. D. Yuan, F. J. Hendler, and E. S. Vitetta, “Characterization of a monoclonal antibody reactive with a subset of human breast tumors,” Journal of the National Cancer Institute, vol. 68, no. 5, pp. 719–728, 1982. View at Google Scholar · View at Scopus
  167. L. Plessers, E. Bosmans, A. Cox et al., “Production and immunohistochemical reactivity of mouse anti-epithelial monoclonal antibodies raised against human breast cancer cells,” Anticancer Research, vol. 10, no. 1, pp. 271–277, 1990. View at Google Scholar · View at Scopus